Resource Summary Report

Generated by NIF on Apr 22, 2025

Eisai

RRID:SCR_003936
Type: Tool

Proper Citation

Eisai (RRID:SCR_003936)

Resource Information

URL: http://www.eisai.com/

Proper Citation: Eisai (RRID:SCR_003936)

Description: A global pharmaceutical company.

Abbreviations: Eisai

Synonyms: Eisai Co. Ltd., EISAI Ltd

Resource Type: commercial organization

Keywords: pharmaceutical, healthcare, drug, oncology, central nervous system, neurology, medicine

Related Condition: Cancer, Epilepsy, Alzheimer's disease, Obesity, Immune-mediated disease, Insomnia

Funding:

Resource Name: Eisai

Resource ID: SCR_003936

Alternate IDs: grid.418767.b, Wikidata: Q29123933, nlx_158312, ISNI: 0000 0004 0599 8842

Alternate URLs: https://ror.org/0469x1750

Record Creation Time: 20220129T080221+0000

Record Last Update: 20250420T014158+0000

Ratings and Alerts

No rating or validation information has been found for Eisai.

No alerts have been found for Eisai.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Blasco B, et al. (2024) High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae. EBioMedicine, 102, 105073.

Söderberg L, et al. (2024) Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Scientific reports, 14(1), 10868.

Silva LL, et al. (2024) Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330. CPT: pharmacometrics & systems pharmacology, 13(1), 106.

Takaesu Y, et al. (2023) Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial. Clinical and translational science, 16(4), 581.

Zhang Y, et al. (2023) Amyloid ?-based therapy for Alzheimer's disease: challenges, successes and future. Signal transduction and targeted therapy, 8(1), 248.

Nojima H, et al. (2022) Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE® system. Annals of clinical and translational neurology, 9(12), 1898.

Nicolo JP, et al. (2021) Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke. BMJ open, 11(5), e043488.

Izsak J, et al. (2021) Differential acute impact of therapeutically effective and overdose concentrations of lithium on human neuronal single cell and network function. Translational psychiatry, 11(1), 281.

Mazzocchetti P, et al. (2020) Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. Neurobiology of disease, 140, 104848.

Guo T, et al. (2020) Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Molecular neurodegeneration, 15(1), 40.

Lu C, et al. (2018) Genistein Ameliorates Scopolamine-Induced Amnesia in Mice Through the Regulation of the Cholinergic Neurotransmission, Antioxidant System and the ERK/CREB/BDNF Signaling. Frontiers in pharmacology, 9, 1153.

Pai M, et al. (2018) Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial. PloS one, 13(6), e0198285.

Kume A, et al. (2016) Probucol dramatically enhances dihydroartemisinin effect in murine malaria. Malaria journal, 15, 472.

Chang AY, et al. (2015) Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series. Breast cancer : basic and clinical research, 9, 19.

Kasai S, et al. (2015) High-Dose ?-Tocopherol Supplementation Does Not Induce Bone Loss in Normal Rats. PloS one, 10(7), e0132059.

Ohsaki Y, et al. (2010) Vitamin K suppresses the lipopolysaccharide-induced expression of inflammatory cytokines in cultured macrophage-like cells via the inhibition of the activation of nuclear factor ?B through the repression of IKK?/? phosphorylation. The Journal of nutritional biochemistry, 21(11), 1120.